For the Inventor, By the Inventor

Enter assignee name

Berkeley, CA, United States of America

Biotime, Inc.

USPTO Granted Patents = 35

% Expired Patents = 11.4

CIPO Patents = 4

EPO Patents = 1

Trademarks = 7

Forward Citations = 725

Loading Chart...

Loading Chart...

13 inventors (with patents filed for the assignee):

Hal Sternberg (32 out of 40 patents)

Paul E Segall (31 out of 33 patents)

Harold D Waitz (31 out of 34 patents)

4. Judith M Segall (23 out of 23 patents)

5. Bruce Cohen (4 out of 4 patents)

6. Michael D West (3 out of 46 patents)

7. Karen B Chapman (2 out of 33 patents)

8. Dana Larocca (1 out of 5 patents)

9. Paola A Bignone (1 out of 3 patents)

10. Thomas Zarembinski (1 out of 1 patent)

11. Isaac Erickson (1 out of 1 patent)

12. Nathaniel Doty (1 out of 1 patent)

13. Evan Y Snyder (1 out of 11 patents)

14. Stanley T Carmichael (3 patents)

15. Andrew N Clarkson (1 patent)

Core Competencies:

Progenitor Cell Lines

Hyaluronan Hydrogels

Transcriptional Regulation

Chondrogenesis

Perfusion Applications

Plasma Expanders

Blood Substitutes

Microcannula

Physiologically Acceptable Solutions

Plasma-Like Solution

Methods of Use

Aqueous Solutions

35 patents: Sort by Forward Citations

1. 10227561 - Methods and compositions for targeting progenitor cell lines (2019-03-12),

2. 10137199 - Thiolated hyaluronan-based hydrogels cross-linked using oxidized glutathione (2018-11-27),

3. 9732128 - Methods of modifying transcriptional regulatory networks in stem cells (2017-08-15),

4. 8685386 - Methods and compositions for in vitro and in vivo chondrogenesis (2014-04-01),

5. 7943292 - Physiologically acceptable aqueous solutions and methods for their use (2011-05-17),

6. 7503913 - Methods and compositions for use in perfusion applications (2009-03-17),

7. 6991624 - Methods and compositions for use in perfusion applications (2006-01-31),

8. 6680305 - Physiologically acceptable aqueous solutions and methods for their use (2004-01-20),

9. 6627393 - Solutions for use as plasma expanders and substitutes (2003-09-30),

10. 6589223 - Method and compositions for use in perfusion applications (2003-07-08),

11. 6506549 - Plasma expanders and blood substitutes (2003-01-14),

12. 6444418 - Plasma-like solution (2002-09-03),

13. 6410218 - Plasma-like solution (2002-06-25),

14. 6406839 - Methods for using a plasma-like solution (2002-06-18),

15. 6387612 - Method of preparing a terminally heat sterilized plasma-like solution (2002-05-14),

Biotime, Inc. is a biotechnology company based in Berkeley, California, specializing in the development of innovative solutions for regenerative medicine and cellular therapies. The organization focuses on advancing technologies related to stem cell research, cellular rejuvenation, and biopreservation. By leveraging its expertise in these domains, Biotime aims to address significant challenges in aging and tissue repair, contributing to the broader field of health and longevity. Its commitment to scientific advancement positions it as a key player in the biotechnology landscape.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

35 Patents

#20 in Berkeley, CA

#2,305 in California

#9,736 in US

#19,137 in the World

Berkeley, CA, United States of America

Biotime, Inc.

Forward Citations = 725

13 inventors:

Hal Sternberg (32 out of 40 patents)

Paul E Segall (31 out of 33 patents)

Harold D Waitz (31 out of 34 patents)

4. Judith M Segall (23 out of 23 patents)

5. Bruce Cohen (4 out of 4 patents)

Please report any incorrect information to [email protected]

Loading…